Business Context and Reporting Period
This Form 8-K is filed by AntriaBio, Inc. (not Rezolute, Inc.) on December 27, 2016. The report details amendments to stock option grants previously made to senior executives in connection with a planned capital raise in the Republic of Korea. The company is currently in negotiations with investment funds but has not secured a binding commitment for the financing.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt). Key capital-related figures include:
- Capital Raised in 2016: Over $17,000,000.
- Target Financing: Initially targeted $10,000,000 to $50,000,000; currently estimated at up to $30,000,000 based on non-binding interest.
- Option Exercise Price: $1.20 per share for all amended grants.
- Option Expiration: October 31, 2026.
Material Changes Versus Prior Period
On October 31, 2016, the Board granted options assuming a potential $50,000,000 financing. On December 27, 2016, the Board amended these grants to reflect a revised financing target of $30,000,000. Consequently, the company rescinded a portion of the previously granted options:
- Nevan Elam: Rescinded 2,400,000 options; retained 3,500,000 Refresh Options and 3,600,000 Prospective Refresh Options.
- Hoyoung Huh: Rescinded 1,800,000 options; retained 4,000,000 Refresh Options and 2,700,000 Prospective Refresh Options.
- Morgan Fields: Rescinded 160,000 options; retained 600,000 Refresh Options and 240,000 Prospective Refresh Options.
- Sankaram Mantripragada: No rescission mentioned; vesting milestones remain unrelated to the financing.
Guidance, Outlook, and Risks
Outlook: The company anticipates raising up to $30,000,000, though no binding commitment exists. Prospective Refresh Options vest based on gross proceeds received by June 30, 2017 (Final Close Date). If the financing target is not met, unvested prospective options will lapse.
Risks and Contingencies:
- Financing Uncertainty: No assurance that the financing will occur or that the target amount will be raised.
- Dilution: Potential dilutive effects from the financing and option exercises.
- Market Conditions: Reliance on investor interest in Korea and current market conditions.
- Forward-Looking Statements: Actual results may differ materially from expectations due to risks detailed in periodic filings.
Investor Verification Checklist
- Verify the current status of the Korean financing negotiations and whether a binding commitment has been secured since December 27, 2016.
- Confirm the total number of shares outstanding and the dilutive impact of the amended option grants (Elam, Huh, Fields) if fully exercised.
- Review the specific vesting milestones for the "Prospective Refresh Options" to understand the conditions required for executives to retain these shares.
- Check subsequent filings for updates on the $30,000,000 financing target and any changes to the $1.20 exercise price.
- Examine the full text of the attached option agreements (Exhibits 10.1 through 10.7) for detailed terms not summarized in this report.